Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsTiny Health, an at-home microbiome testing startup, just closed a $33M Series B to expand its research, provider education, and enterprise partnerships. The company—already partnered with Stanford Medicine, Mayo Clinic, and Mass General—also launched a $5M Microbiome Research Program. With nearly 200,000 microbiome profiles in its dataset, Tiny is eyeing research into IBD, menopause, and GLP-1 drug response.
Tiny Health, a consumer-facing microbiome testing company, has closed an oversubscribed $33M Series B led by B Capital, bringing its total funding to $46M. The capital will fuel research expansion, provider education, B2B platform scaling, and development of its patient-facing AI agent. Alongside the raise, Tiny launched a $5M Microbiome Research Program to help clinicians and scientists layer microbiome data onto their existing work.
Founded in 2022, Tiny started with tests for babies and moms before expanding to adult gut and vaginal microbiome testing—adult tests now outpace pediatric ones in volume. Its AI-powered platform, trained on nearly 200,000 microbiome profiles, delivers personalized recommendations on diet, supplements, and lifestyle. A 2025 randomized controlled trial published in Pediatric Allergy and Immunology found that targeted microbiome interventions reduced infants' odds of developing eczema by 83%.
By the Numbers:
Why it matters: As the gut microbiome's role in immune health, metabolism, and chronic disease becomes clearer, Tiny Health is positioning itself at the intersection of consumer wellness and clinical-grade research—with major health system partnerships and a growing evidence base to back it up.